The goal of this review is to highlight the impact of innovative antihyperglycemic treatments on the function and structure of vital organs in animals with experimentally induced T2D, focusing on next-generation agents, such as SGLT-2 inhibitors and GLP-1 agonists, and their effects on organ damage associated with DM. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.